Cipla wins R2 billion of state ARV tender

Cipla wins R2 billion of state ARV tender

Cipla, the third largest pharmaceutical company in South Africa, today announced that it has been awarded R2 billion share of the South African Government’s 2015-17 National ARV tender. The contract is effective from the 1st of April 2015 and will run for a period of three years.

CEO of Cipla Medpro, Paul Miller, says that Cipla is proud to have been recognised once again as a preferred partner of the State in the national fight against HIV and Aids. “Cipla is known as a pioneer of fixed dose combinations following Cipla’s Dr Yusuf Hamied’s accomplishment of making Aids medication available for a dollar a day in 2001.” Cipla also went further and made this triple combination available in the world’s first 3-in-1 combination ARV.

“We intend to continue this proud tradition and build on the foundation laid to continue our quest of providing affordable healthcare to all,” Miller adds.

This latest Government tender win is the third in the last year for the growing pharmaceutical company, and follows Cipla Medpro winning a  R280 million state therapeutic drug tender (August 2014), a R345 million national respiratory tender (June 2014).

The medication will be produced at its state-of-the-art, 23 000 square meter manufacturing site, Cipla Medpro Manufacturing (CMM), which is based in Kwazulu-Natal. “CMM employs approximately 300 staff members, 98% of which are previously disadvantaged”.

The organisation is currently developing unique fixed dose combinations (FDCs) and formulations and will continue to promote new molecules and innovative fixed-dose combinations as well as licencing agreements to ensure fair returns for investors and affordable prices for patients.

“We are extremely proud to have won this tender which is not only testament to our high quality product portfolio, but is also in line with Cipla’s ethos of advancing healthcare for all South Africans. We look forward to continuing this partnership with government – united in the fight against Aids,” concludes Subhanu Saxena, MD & Global CEO of Cipla Limited.


In the interest of our patients, in accordance with South African law and our commitment to expertise, MediHub cannot subscribe to the practice of online diagnosis. Please consult a medical professional for specific medical advice. If you have any major concerns, please see your doctor for an assessment. If you have any cause for concern, your GP will be able to direct you to the appropriate specialists.

Cipla Communications brings you the latest news from the Press, keeping you up to date with what's happening in the world of Cipla.
Visit the official COVID-19 government website to stay informed: